tbuckley/cabot-search huggingface dataset:
Significance of necrosis in grading of anaplastic oligodendroglial tumors: A clinicopathological and genetic study of 916 high-grade gliomas
Authors: C. R. Miller, C. P. Dunham, B. W. Scheithauer, A. Perry
Journal: Journal of Clinical Oncology (2006)

1502 Background: High-grade gliomas (HGG, WHO grades III-IV) are morphologically and genetically diverse, with survivals ranging from months to decades. Although WHO 2000 grading criteria are well established for pure astrocytomas [anaplastic astrocytoma (AA) and glioblastoma (GBM)], those for oligodendroglial neoplasms [anaplastic oligoastrocytoma (AOA) and oligodendroglioma (AO)] remain subjective, there being a debate regarding the existence of a grade IV variant based on the finding of necrosis, particularly with pseudopalisading (PPN). Methods: Overall survival of 916 adult (&gt;20 yr) patients diagnosed between 1990 and 2005 with supratentorial HGG (77 AA, 481 GBM, 183 AOA, 175 AO) was analyzed by uni- (log-rank) and multivariate (Cox proportional hazards) models for significance of the following factors: microvascular proliferation, necrosis, patient age, surgery (stereotactic vs. open), location, primary vs. secondary tumor, year of diagnosis, and chromosome 1p and 19q losses by fluorescence in situ hybridization. Results: Necrosis was a statistically significant predictor of poor survival on multivariate analyses in AOA (P=0.035), but not in AO (log-rank P=0.048, Cox P=0.9), while PPN showed a trend towards significance on multivariate analysis only in AOA (P=0.096). Other independent predictors on multivariate analysis included age, grade, surgery type, and year of diagnosis for AA/GBM and age, primary tumor, and 1p/19q codeletion for both AOA and AO (P&lt;0.05). Median survival for AOA patients whose tumors featured necrosis (20.7 mo) was significantly worse than their counterparts lacking necrosis (&gt;104 mo); survival of the latter was more similar to that of AO (83.5 mo), whereas in the former it was better than GBM (10.5 mo) (log-rank P&lt;0.0001). Conclusions: Stratification of oligoastrocytomas, but not of pure oligodendrogliomas, into grades III (AOA) and IV (GBM with oligodendroglial features) on the basis of necrosis is prognostically justified and is more accurate than the current approach of using a single anaplastic grade. These data provide impetus for the modification of present WHO criteria. No significant financial relationships to disclose.
Moose on the loose: checklist for meta-analyses of observational studies
Authors: E.J. van Zuuren, Z. Fedorowicz
Journal: British Journal of Dermatology (2016)

The aims and scope of the British Journal of Dermatology clearly underline that 'The BJD strives to publish the highest-quality dermatological research', with an understanding that submissions need to adhere to internationally accepted standards and quality criteria.Compliance with these criteria will expedite the transition of a submission through the peer-reviewing process, and most importantly add value to a manuscript.Most researchers conducting clinical trials will already be familiar with the Consolidated Standards of Reporting Trials (CONSORT) guidelines for randomized controlled trials (RCTs) and with the STrengthening the Reporting of Observational studies in Epidemiology (STROBE) guidelines for observational studies.However, neither of these guidelines is directly applicable to systematic reviews.In 2009 the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement was released in several key international journals such as the BMJ, PLoS Medicine, Annals of Internal Medicine and Journal of Clinical Epidemiology. 1 This important step has progressively enhanced the quality of conduct and reporting of systematic reviews. 1 Systematic reviews and meta-analyses have gained in importance and are increasingly used as the basis for clinical guideline development.Conducting a systematic review can be very time-consuming and it is important that the methodology as well as the results are reported in a structured standardized and above all transparent manner.The PRISMA checklist, which consists of 27 items, provides clear guidance to review authors on how to improve the reporting of their systematic review and meta-analysis. 1 PRISMA is predominantly used for systematic reviews and meta-analyses evaluating RCTs.However, not all evidence can be synthesized from RCTs or in many cases it is not feasible to conduct RCTs or they are not available. 2The results from observational studies can be regarded as complementary to the findings of RCTs and may more accurately reflect the effects in the real world by providing long-term data on both the effectiveness and adverse events of interventions. 3,4Observational studies can also offer additional advantages over other study designs by identifying and summarizing infrequent or rare adverse events, more especially as the number of patients is generally much larger (especially when large databases are used).This form of study design may also include a more diverse and clinically heterogeneous patient population and a longer follow-up period. 4However, the major limitations of observational studies are their inability to avoid or balance sources of bias (e.g.selection bias) and in eliminating possible confounding factors
TCT-474 Ten-year follow-up of the Xience stent in 7655 consecutive patients: single center registry results
Authors: Daniela Trabattoni, Franco Fabbiocchi, Piero Montorsi, Alessandro Lualdi, Giuseppe Calligaris, Paolo Mario Ravagnani, Stefano Galli, Cristina Ferrari, Paolo Olivares, Antonio Bartorelli
Journal: Journal of the American College of Cardiology (2016)
Public referendum on drug prices in the US: will it bring relief?
Authors: Thomas J Hwang, Aaron S Kesselheim
Journal: BMJ (2016)

Thomas Hwang and Aaron Kesselheim assess how California’s proposed new law on drug pricing could affect healthcare costs in the US and beyond Concerns over the rising cost of new medicines have prompted calls for a more sustainable system of drug pricing.1 2 3 Public unease is particularly acute in the US, where brand name drug prices are the highest in the world and the costs are increasingly being passed on to patients.4 This has led to federal and state policy efforts seeking to tackle high drug prices.5 6 In November, one such policy initiative will be put to a vote: voters in California will decide whether preferential pricing provided to the US Department of Veterans Affairs should also be available to other public payers in the state. Successful ballot measures in California have historically triggered national reforms (box 1). The outcomes of the California referendum are also likely to have global implications, because attempts to reduce drug prices in the US could have a ripple effect on the prices negotiated by other countries.7 We examine the potential savings from the proposed change. #### Box 1: Importance of policy reforms in California California has a long history as a laboratory for national policy reforms. It is the most populous US state (about 39 million people), accounting for roughly 12% of the US population. California also grants its voters the power to initiate or repeal legislation by referendum. Examples of influential health policy changes in California include:
TCT-410 Different Vascular Healing Process between Bioabsorbable Polymer-coated Everolimus-Eluting Stents versus Bioresorbable Vascular Scaffolds via Optical Coherence Tomography and Coronary Angioscopy: Early Results from ENdothelial Healing Assessment With Novel Coronary tEchnology (ENHANCE study)
Authors: Wan Azman Wan Ahmad, Takaharu Nakayoshi, Ahmad Syadi Mahmood Zuhdi, Muhammad Dzafir Ismail, Yoshihiro Fukumoto, Takafumi Ueno
Journal: Journal of the American College of Cardiology (2016)
Anti-CD3 Activated T Cells from Cord Blood Can Be Expanded Ex Vivo and Armed with Bispecific Antibodies To Lyse Her2/Neu + and CD20+ Targets: A Strategy for Providing Anti-Tumor/Lymphoma Effects after Cord Blood Transplant.
Authors: Carly B. Sorenson, Thomas D. Frandsen, Suanne Dorr, Voravit Ratanatharathorn, Joseph P. Uberti, Lawrence G. Lum
Journal: Blood (2007)
TCT-836 Endothelial Cell Coverage and Inflammation Comparing COBRA Polyzene-F (PzF) Coated Stent to Durable Fluoropolymer and Biodegradable Polymer Drug-Eluting Stents in a Rabbit Model
Authors: Kazuyuki Yahagi, Frank Kolodgie, Qi Cheng, Eduardo Acampado, Sho Torii, Hiroyoshi Mori, Maria Romero, Aloke Finn, Renu Virmani
Journal: Journal of the American College of Cardiology (2016)
Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders: BCL2 as a prognostic marker
Authors: A. B. Oton, W. Hong, M. Melhem, D. George, K. Foon, I. M. Ghobrial
Journal: Journal of Clinical Oncology (2007)

8073 Background: PTLD is the most serious hematological complications of solid-organ transplantation. We determined clinical and immunohistopathological prognostic factors for overall survival (OS) in patients with PTLD. Methods: Eighty-four patients with PTLD between 1980 and 2004 at University of Pittsburgh were identified. Immunohistochemistry staining was performed on tumor at diagnosis for BCL2, BCL6, cMYC, p53, PS6k, HSP90 and NFkB. Univariate associations between individual clinical and immunohistopathological features and OS were compared using Cox proportional hazard models. Survival curves were generated via the method of Kaplan-Meier. Results: The median age at the time of diagnosis of PTLD was 53 years. Thirty four percent of patients presented with early PTLD. Sixty-four percent of patients were EBV positive by in situ hybridization. Lung transplant was significantly related to grafted organ involvement (p=0.035). Lung and multiorgan transplants were associated with a higher risk for early PTLD (p=0.0033 and p=0.054), while renal transplant was associated with risk for late PTLD (p=0.0011). The median survival for all patients was 20.8 months, 95% CI: (7.4–77.6). On univariate analysis for OS, poor prognostic factors were identified: age of transplant &gt;60 yr (p=0.02), multiorgan transplant (p=0.02), ECOG&gt;2 (p&lt;0.0001), grafted organ involvement and extranodal disease at the time of diagnosis (p&lt;0.011), early PTLD (p&lt;0.0001), and elevated white blood cell count (WBC) 1 month prior to diagnosis (p=0.01). Good prognostic factors included late PTLD, monomorphic disease, CD20 positive and rituximab use. Only BCL2 strongly correlated with prognosis (p=0.002). A final clinico-pathological model for survival was constructed using three factors: ECOG &gt;2, elevated WBC one month prior diagnosis and BCL2 overexpression. Patients with these three risk factors had median survival of 10 days (95% CI: 0–41), in comparison with patients with none of these risk factors had median survival of 1,414 days. Conclusions: Patients who had 3 factors ECOG &gt;2, elevated WBC one month prior diagnosis, and BCL2 overexpression in tumor tissue had worse median survival than the patients with none of these three factors. No significant financial relationships to disclose.
EVALUACION PROSPECTIVA DE LA INFLUENCIA DEL ESPECIALISTA EN FORMACION EN EL ÉXITO Y LA TASA DE COMPLICACIONES DE LA CPRE
Authors: E Vazquez-Sequeiros, JR Foruny, JA Gonzalez Martin, L Aguilera, V Defarges, V Benita, D Boixeda, A Albillos
Journal: Endoscopy (2016)

Introducción: Se ha sugerido que la intervención de médicos especialistas en formación en la CPRE (intento de canulación por residente: ICPR) podría asociarse con menor eficacia y más complicaciones.
TCT-200 Correlation of Admission Heart Rate With Angiographic and Clinical Outcomes by Culprit Coronary Artery in Patients With STEMI Undergoing Primary PCI: The HORIZONS-AMI Trial
Authors: Monica Embacher, Ioanna Kosmidou, Rushad Dordi, Bjorn Redfors, Jose Dizon, Roxana Mehran, Ori Ben-Yehuda, Gregg Stone
Journal: Journal of the American College of Cardiology (2016)
Tuberculosis prevention must integrate technological and basic care innovation
Authors: Heidi Albert, Ruvandhi R. Nathavitharana, Claudia M. Denkinger, Chris Isaacs, Catharina C. Boehme
Journal: European Respiratory Journal (2016)

P.H. Mason and colleagues highlight the fact that "new technology alone cannot solve the [tuberculosis] epidemic" and that integrated and community-driven solutions are needed to meet tuberculosis (TB) care and treatment goals. The authors highlight an example of community-wide screening using portable radiography in the pre-antibiotic treatment era, with patients being prescribed rest, diet, exercise and fresh air, leading to a reduction in TB prevalence in the intervention area. We concur with the authors' view that a focus purely on introducing new technologies, be they diagnostics, drugs or vaccines, will not have the desired impact on patient outcomes or public health. In our article, we put forward the proposition that a holistic solution is needed to ensure adequate impact of new diagnostics on patient-important outcomes [1]. For TB patients, especially those with multidrug-resistant disease, who require extremely long and arduous treatment regimens, social support, adequate diet and management of other pre-existing conditions, are essential components of a patient's care, without which patients are unlikely to be successfully treated. Complementary innovations in patient support and technology solutions are needed to end TB <http://ow.ly/aUrC304opl8>
TCT-540 Diagnostic Accuracy of Stress Echocardiography Compared With Invasive Coronary Angiography With Fractional Flow Reserve for the Diagnosis of Haemodynamically Significant Stenosis(Es) in Patients With Known or Suspected Coronary Artery Disease
Authors: Sothinathan Gurunathan, Grace Young, Nikos Karogiannis, Ahmed Elghamaz, Roxy Senior
Journal: Journal of the American College of Cardiology (2016)
Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations
Authors: Ayalew Tefferi, Ramy Abdelrahman, Christy Finke, Terra L. Lasho, Kebede H. Begna, Aref Al-Kali, William J Hogan, Mark R Litzow, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani
Journal: Blood (2015)
TCT-425 Bioresorbable vascular scaffold technology for small vessel coronary artery disease: results from the Italian multicenter RAI Registry
Authors: Giulia Masiero, Giuseppe Tarantini, Marco Mojoli, Bruno Loi, Bernardo Cortese, Attilio Varricchio, Alfonso Ielasi, Francesco Pisano, Pietro Mazzarotto, Paolo Calabro', Roberto Gistri, Alessandro Durante, Davide Piraino, Gabriele Tumminello, Valerio Lucci, Luciano Moretti, Leonardo Misuraca, Giampaolo Pasquetto, Alessandro Colombo, Maurizio Ferrario, Sebastian Coscarelli, Zoran Olivari, Annamaria Nicolino, Luigi Piatti, Paola Tellaroli, Donatella Corrado, Giuseppe Steffenino
Journal: Journal of the American College of Cardiology (2016)
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α
Authors: Yana G. Najjar, Patricia Rayman, Xuefei Jia, Paul G. Pavicic, Brian I. Rini, Charles Tannenbaum, Jennifer Ko, Samuel Haywood, Peter Cohen, Thomas Hamilton, C. Marcela Diaz-Montero, James Finke
Journal: Clinical Cancer Research (2016)

Purpose: Little is known about the association between myeloid-derived suppressor cell (MDSC) subsets and various chemokines in patients with renal cell carcinoma (RCC) or the factors that draw MDSC into tumor parenchyma.Experimental Design: We analyzed polymorphonuclear MDSC (PMN-MDSC), monocytic MDSC (M-MDSC), and immature MDSC (I-MDSC) from the parenchyma and peripheral blood of 48 patients with RCC, isolated at nephrectomy. We analyzed levels of IL1β, IL8, CXCL5, Mip-1α, MCP-1, and Rantes. Furthermore, we performed experiments in a Renca murine model to assess therapeutic synergy between CXCR2 and anti-PD1 and to elucidate the impact of IL1β blockade on MDSC.Results: Parenchymal PMN-MDSC have a positive correlation with IL1β, IL8, CXCL5, and Mip-1α, and I-MDSC correlate with IL8 and CXCL5. Furthermore, peripheral PMN-MDSC correlate with tumor grade. Given that PMN-MDSC express CXCR2 and parenchymal PMN-MDSC correlated with IL8 and CXCL5, we assessed the response of CXCR2 blockade with or without anti-PD1. Combination therapy reduced tumor weight and enhanced CD4+ and CD8+ T-cell infiltration. In addition, anti-IL1β decreased PMN-MDSC and M-MDSC in the periphery, PMN-MDSC in the tumor, and peripheral CXCL5 and KC. Anti-IL1β also delayed tumor growth.Conclusions: Parenchymal PMN-MDSC have a positive correlation with IL1β, IL8, CXCL5, and Mip-1α, suggesting they may attract PMN-MDSC into the tumor. Peripheral PMN-MDSC correlate with tumor grade, suggesting prognostic significance. Anti-CXCR2 and anti-PD1 synergized to reduce tumor weight and enhanced CD4+ and CD8+ T-cell infiltration in a Renca murine model, suggesting that CXCR2+ PMN-MDSC are important in reducing activity of anti-PD1 antibody. Finally, anti-IL1β decreases MDSC and delayed tumor growth, suggesting a potential target for MDSC inhibition. Clin Cancer Res; 23(9); 2346-55. ©2016 AACR.
TCT-134 Mechanical Chest Compressions as a Bridge to Percutaneous Extracorporeal Life Support Increase Return of Spontaneous Circulation in Patients with Cardiac Arrest
Authors: Joseph Venturini, Elizabeth Retzer, Raider Estrada, Janet Friant, David Beiser, Dana Edelson, Jonathan Paul, John Blair, Sandeep Nathan, Atman Shah
Journal: Journal of the American College of Cardiology (2016)
TCT-248 Pacemaker Implantation in Transcatheter Aortic Valve Replacement vs. Sutureless Surgical Aortic Valve Replacement: A Meta-analysis
Authors: Mohit Turagam, Poonam Velagapudi, Harsh Agrawal, Mayank Mittal, Natraj Katta, J. Dawn Abbott, Kul Aggarwal
Journal: Journal of the American College of Cardiology (2016)
Bone Marrow Failure in Fanconi Anemia from Hyperactive TGF-β Signaling
Authors: Haojian Zhang, David Kozono, Kevin O'Connor, Sofia Vidal-Cardenas, Abigail Hamilton, Emily Gaudiano, Joel S. Greenberger, Markus Grompe, Kalindi Parmar, Alan D. D'Andrea
Journal: Blood (2014)
Analysis of Non-Expressed IGK Locus Rearrangements in Chronic Lymphocytic Leukemia Indicates a Role for Secondary Rearrangements in Shaping the Expressed Immunoglobulin Repertoire.
Authors: Chrysoula Belessi, Kostas Stamatopoulos, Katerina Hatzi, Anastasia Hadzidimitriou, Fotini Marantidou, Tatjana Smilevska, Niki Stavroyianni, Anastasia Athanasiadou, Evangelia Kalagiakou, Garyfallia Kokkini, Christos Georgopoulos, George Paterakis, Riad Saloum, Athanasios Fassas, Achilles Anagnostopoulos, Nikolaos Laoutaris
Journal: Blood (2004)
TCT-684 Frailty Profile is Independently Associated with Higher Cost for Patients undergoing Transcatheter Aortic Valve Replacement for Symptomatic Severe Aortic Stenosis: a Single Center Experience
Authors: Jay Patel, Sandeep Banga, Min-Chul Kim, Keattiyoat Wattanakit, Marco A. Barzallo, Sudhir Mungee
Journal: Journal of the American College of Cardiology (2016)
Funding shortfalls put target to end TB epidemic by 2035 at risk
Authors: Sophie Cousins
Journal: BMJ (2016)

Global funding for tuberculosis (TB) research and development has fallen to its lowest level since 2008, raising doubts about whether the global goal of ending the epidemic by 2035 will be possible.

The 2016 report on tuberculosis research funding trends 2005-15, published by Treatment Action Group, found that funding dropped to $620.6m (£570.9m; €570m) in 2015, down more than $50m from the previous year.1

Mike Frick, TB/HIV senior project officer at Treatment Action Group, told The BMJ that the fall in funding was a result of …
TCT-61 Long-term Outcomes of Patients with Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion
Authors: Kambis Mashayekhi, aurel toma, Michael Behnes, Michael Gick, Miroslaw Ferenc, Heinz Joachim Buettner, Franz-Josef Neumann
Journal: Journal of the American College of Cardiology (2016)
TCT-733 Predictors of Permanent Pacemaker Implantation in Patients Treated in Routine Clinical Practice with the Repositionable and Fully Retrievable Lotus Valve
Authors: Nicolas Van Mieghem, Lennart van Gils, Jochen Wöhrle, David Hildick-Smith, Sabine Bleiziffer, Dan Blackman, Mohamed Abdel-Wahab, Axel Linke, Hüseyin Ince, Peter Wenaweser, Nikos Werner, Dominic J. Allocco, Keith D. Dawkins, Volkmar Falk, MaryEllen Klusacek
Journal: Journal of the American College of Cardiology (2016)
Inflammatory monocytes hinder antiviral B cell responses
Authors: Stefano Sammicheli, Mirela Kuka, Pietro Di Lucia, Nereida Jiménez de Oya, Marco De Giovanni, Jessica Fioravanti, Claudia Cristofani, Carmela G. Maganuco, Benedict Fallet, Lucia Ganzer, Laura Sironi, Marta Mainetti, Renato Ostuni, Kevin Larimore, Philip D. Greenberg, Juan Carlos de la Torre, Luca G. Guidotti, Matteo Iannacone
Journal: Science Immunology (2016)

Antibodies are critical for protection against viral infections. However, several viruses, such as lymphocytic choriomeningitis virus (LCMV), avoid the induction of early protective antibody responses by poorly understood mechanisms. Here we analyzed the spatiotemporal dynamics of B cell activation to show that, upon subcutaneous infection, LCMV-specific B cells readily relocate to the interfollicular and T cell areas of the draining lymph node where they extensively interact with CD11b+Ly6Chi inflammatory monocytes. These myeloid cells were recruited to lymph nodes draining LCMV infection sites in a type I interferon-, CCR2-dependent fashion and they suppressed antiviral B cell responses by virtue of their ability to produce nitric oxide. Depletion of inflammatory monocytes, inhibition of their lymph node recruitment or impairment of their nitric oxide-producing ability enhanced LCMV-specific B cell survival and led to robust neutralizing antibody production. In conclusion, our results identify inflammatory monocytes as critical gatekeepers that prevent antiviral B cell responses and suggest that certain viruses take advantage of these cells to prolong their persistence within the host.